ES2337935T3 - Comprimidos de accion retardada con hidromorfona. - Google Patents

Comprimidos de accion retardada con hidromorfona. Download PDF

Info

Publication number
ES2337935T3
ES2337935T3 ES07021788T ES07021788T ES2337935T3 ES 2337935 T3 ES2337935 T3 ES 2337935T3 ES 07021788 T ES07021788 T ES 07021788T ES 07021788 T ES07021788 T ES 07021788T ES 2337935 T3 ES2337935 T3 ES 2337935T3
Authority
ES
Spain
Prior art keywords
layer
active ingredient
release
active substance
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07021788T
Other languages
English (en)
Spanish (es)
Inventor
Marc Zingraff
Markus Reher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acino Pharma AG
Original Assignee
Acino Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2337935(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acino Pharma AG filed Critical Acino Pharma AG
Application granted granted Critical
Publication of ES2337935T3 publication Critical patent/ES2337935T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
ES07021788T 2007-11-09 2007-11-09 Comprimidos de accion retardada con hidromorfona. Active ES2337935T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021788A EP2057984B1 (de) 2007-11-09 2007-11-09 Retardtabletten mit Hydromorphon

Publications (1)

Publication Number Publication Date
ES2337935T3 true ES2337935T3 (es) 2010-04-30

Family

ID=39272211

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07021788T Active ES2337935T3 (es) 2007-11-09 2007-11-09 Comprimidos de accion retardada con hidromorfona.
ES08847385T Active ES2374690T3 (es) 2007-11-09 2008-10-24 Comprimidos de liberación retardada con hidromorfona.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08847385T Active ES2374690T3 (es) 2007-11-09 2008-10-24 Comprimidos de liberación retardada con hidromorfona.

Country Status (15)

Country Link
US (1) US20100247647A1 (pl)
EP (3) EP2057984B1 (pl)
JP (1) JP2011503017A (pl)
AT (2) ATE455538T1 (pl)
AU (1) AU2008324466A1 (pl)
CA (1) CA2704646C (pl)
DE (1) DE502007002695D1 (pl)
DK (2) DK2057984T3 (pl)
ES (2) ES2337935T3 (pl)
HR (1) HRP20100157T1 (pl)
PL (1) PL2057984T3 (pl)
PT (1) PT2057984E (pl)
RS (1) RS51313B (pl)
SI (1) SI2057984T1 (pl)
WO (1) WO2009059701A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP1623703B1 (en) 1999-10-29 2011-10-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
MX348361B (es) 2009-12-17 2017-06-07 Cima Labs Inc Formulaciones resistentes al abuso.
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
ES2444591T3 (es) * 2010-10-28 2014-02-25 Acino Pharma Ag Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
WO2014034929A1 (ja) * 2012-09-03 2014-03-06 第一三共株式会社 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2016094358A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20210015753A1 (en) 2017-11-27 2021-01-21 Dsm Ip Assets B.V. Freeze-dried multiparticulate solid dosage form
TW201943410A (zh) 2018-04-10 2019-11-16 荷蘭商帝斯曼知識產權資產管理有限公司 具有彈性結構之多顆粒固體劑型
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
JP2007520421A (ja) * 2003-06-26 2007-07-26 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 経口投与用放出制御型薬物送達システム
US20050074493A1 (en) * 2003-10-03 2005-04-07 Mehta Atul M. Extended release formulations of opioids and method of use thereof
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20070104789A1 (en) * 2005-11-04 2007-05-10 Donald Spector Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
EA020867B1 (ru) * 2006-03-06 2015-02-27 Поузен Инк. Лекарственные формы для введения комбинаций лекарственных средств

Also Published As

Publication number Publication date
DK2217210T3 (da) 2012-02-13
HRP20100157T1 (hr) 2010-04-30
EP2425822B1 (de) 2012-12-19
WO2009059701A2 (de) 2009-05-14
DE502007002695D1 (de) 2010-03-11
EP2057984A1 (de) 2009-05-13
ATE455538T1 (de) 2010-02-15
EP2057984B1 (de) 2010-01-20
CA2704646C (en) 2016-04-05
US20100247647A1 (en) 2010-09-30
EP2217210A2 (de) 2010-08-18
EP2217210B1 (de) 2011-12-14
PT2057984E (pt) 2010-03-10
RS51313B (sr) 2010-12-31
DK2057984T3 (da) 2010-05-03
ATE536862T1 (de) 2011-12-15
JP2011503017A (ja) 2011-01-27
WO2009059701A3 (de) 2009-07-16
ES2374690T3 (es) 2012-02-21
AU2008324466A1 (en) 2009-05-14
EP2425822A1 (de) 2012-03-07
CA2704646A1 (en) 2009-05-14
SI2057984T1 (sl) 2010-04-30
PL2057984T3 (pl) 2010-05-31

Similar Documents

Publication Publication Date Title
ES2337935T3 (es) Comprimidos de accion retardada con hidromorfona.
ES2625092T3 (es) Formas de dosificación orales resistentes a la adicción y método de uso de las mismas
ES2283821T3 (es) Composicioon farmaceutica solida que contiene un principio activo lipofilo y su procedimiento de preparacion.
RU2504362C2 (ru) Системы доставки лекарственных веществ, включающие в себя слабоосновные лекарственные вещества и органические кислоты
WO2006082523A2 (en) Pharmaceutical sustained release composition of metformin
WO2013076216A1 (en) Controlled release particles comprising dimethyl fumarate
US20190290629A1 (en) Niraparib sustained and controlled release pharmaceutical composition and use thereof
KR20070052300A (ko) 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
BRPI0716436B1 (pt) sistema de liberação controlada e método para fabricação do mesmo
ES2616115T3 (es) Forma farmacéutica oral de liberación controlada que comprende oxicodona
KR20120094882A (ko) 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
WO2018108157A1 (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
US10918630B2 (en) Delayed release pharmaceutical composition of pantoprazole and process for formulation thereof
ES2663357T3 (es) Formulaciones de mazindol
WO2016000608A1 (zh) 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物
WO2010023690A2 (en) Prolonged release formulation of amisulpride
ES2944535T3 (es) Formulación de afabicina, método para preparar la misma
US20180344648A1 (en) Clobazam tablet formulation and process for its preparation
ES2376095B1 (es) Pellets entéricos de duloxetina.
ES2444591T3 (es) Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
JP6129184B2 (ja) ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
US20170333350A1 (en) Pharmaceutical Composition Comprising Dabigatran Etexilate, And Preparation Method, Solid Preparation And Use Thereof
EP3275434B1 (en) An extended release oral dosage form
EP2438920A1 (en) Controlled-Release Formulations of Quetiapine
EA045511B1 (ru) Состав с афабицином, способ его получения и его применение